COST EFFECTIVENESS OF EMPAGLIFLOZIN/LINAGLIPTIN AS 2ND-LINE THERAPY FOR ADULTS WITH TYPE 2 DIABETES
May 1, 2016, 00:00 AM
10.1016/j.jval.2016.03.1297
https://www.valueinhealthjournal.com/article/S1098-3015(16)01365-6/fulltext
Section Title :
Diabetes/Endocrine Disorders - Cost Studies
Section Order :
638
First Page :
A202
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01365-6&doi=10.1016/j.jval.2016.03.1297